Nat Peckett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nat Peckett has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Aslihan Bastem Akan
Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, UK
1 shared publication- Caroline V. Billard
CRUK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK
1 shared publication Colin W. Steele
Cancer Research UK Scotland Institute, Glasgow, UK
1 shared publicationDonnchadh S. Dunican
MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, UK
1 shared publication- Farhat Vanessa Nasim Din
Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh , Edinburgh
1 shared publication - Fausto D. Velez-Bravo
KU Leuven
1 shared publication
Latest Publications
- Open Access
- 4 June 2025
- Published by Springer Nature in Nature
- Vol. 644 (8076) , 547-556
Loss of colonic fidelity enables multilineage plasticity and metastasis
Cancer cell plasticity enables the acquisition of new phenotypic features and is implicated as a major driver of metastatic progression1,2. Metastasis occurs mostly in the absence of additional genetic alterations3–5, which suggests that epigenetic mechanisms are important6. However, they remain poorly defined. Here we identify the chromatin-remodelling enzyme ATRX as a key regulator of colonic lineage fidelity and metastasis in colorectal cancer. Atrx loss promotes tumour invasion and metastasis, concomitant with a loss of colonic epithelial identity and the emergence of highly plastic mesenchymal and squamous-like cell states. Combined analysis of chromatin accessibility and enhancer mapping identified impairment of activity of the colonic lineage-specifying transcription factor HNF4A as a key mediator of these observed phenotypes. We identify squamous-like cells in human patient samples and a squamous-like expression signature that correlates with aggressive disease and poor patient prognosis. Collectively, our study defines the epigenetic maintenance of colonic epithelial identity by ATRX and HNF4A as suppressors of lineage plasticity and metastasis in colorectal cancer.
- 4 June 2025
- Published by Springer Nature in Nature
- Vol. 644 (8076) , 547-556
Open AccessLoss of colonic fidelity enables multilineage plasticity and metastasis
Cancer cell plasticity enables the acquisition of new phenotypic features and is implicated as a major driver of metastatic progression1,2. Metastasis occurs mostly in the absence of additional genetic alterations3–5, which suggests that epigenetic mechanisms are important6. However, they remain poorly defined. Here we identify the chromatin-remodelling enzyme ATRX as a key regulator of colonic lineage fidelity and metastasis in colorectal cancer. Atrx loss promotes tumour invasion and metastasis, concomitant with a loss of colonic epithelial identity and the emergence of highly plastic mesenchymal and squamous-like cell states. Combined analysis of chromatin accessibility and enhancer mapping identified impairment of activity of the colonic lineage-specifying transcription factor HNF4A as a key mediator of these observed phenotypes. We identify squamous-like cells in human patient samples and a squamous-like expression signature that correlates with aggressive disease and poor patient prognosis. Collectively, our study defines the epigenetic maintenance of colonic epithelial identity by ATRX and HNF4A as suppressors of lineage plasticity and metastasis in colorectal cancer.